课题基金 / 基金详情

Developmental Research Program

Developmental Research Program
发展研究计划
批准号:
10286763
负责人:
George Ioannou
金额:
$6.52万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-06 至 2024-08-31

项目摘要

项目成果

George Ioannou的其他基金

相似基金

相关文献

中文摘要
翻译
摘要:研发项目核心 美国印第安人/阿拉斯加原住民肝癌发展研究计划(AI/AN) 差异(LI-CAD)P20计划将支持有潜力开辟新领域的早期项目 转化型肝癌研究,并最终有助于降低发病率和死亡率并改善 肝细胞癌患者的生活质量。在DRP下资助的项目旨在 迅速提出一个新的想法或概念,有可能对我们对肝脏的理解产生重大影响 癌症消除差异,改善人工/再生障碍性人肝细胞癌的监测、早期发现和治疗 从而降低或消除与肝癌相关的死亡率。刚果民主共和国的基础设施将建立机制 快速响应LI-CAD P20计划机构内的翻译研究机会 支持提出假设或确认可行性,以证明更大的资源投资是合理的。 发展项目将包括基础科学、临床科学和以人口为基础的研究, 并将在LI-CAD站点和其他机构之间通过P20程序和肝脏中的孢子建立合作 癌症和差异研究。 发展项目可能包括广泛的肝癌研究和治疗领域,包括 基础科学、病因学和预防(初级和次级)、早期发现、预后、治疗和 生存能力。总的来说,DRP的结构是为了加强LI-CAD站点和Initiate之间的合作 与其他机构的互动与P20程序和肝癌的孢子。DRP建议书将是 基于他们将原始想法或概念转化为翻译研究项目的潜力而获得支持 将成功获得独立资金,无论是在随后的P50内,还是从其他政府或 基金会消息来源。此外,DRP旨在吸引具有不同科学知识的高级调查人员 转化型肝癌研究的专业知识和初级调查人员。 发展研究方案的具体目标是: 1.促进创新、有影响力的早期研究研究的发展,包括 与LI-CAD机构的基础、临床和人口科学家的多学科互动; 2.提供资金(1-2年)和基础设施(例如,生物检疫剂、生物统计学支持),以进行快速检测 原创研究人员发起的项目在所有肝癌研究领域的可行性; 3.优先提供资金,以迅速开发新的机会或支持具有战略重要性的特定领域 推进LI-CAD P20计划的翻译研究目标;以及 4.监督(和促进)每个DRP项目的进度,并考虑将其推进到完整的P50 孢子项目。
英文摘要
ABSTRACT: DEVELOPMENTAL AND RESEARCH PROGRAM CORE The Developmental Research Program (DRP) of the Liver Cancer in American Indians/Alaska Natives (AI/AN) Disparities (Li-CAD) P20 Program will support early-phase projects that have the potential to open new areas of translational liver cancer research and ultimately, contribute to reducing morbidity and mortality and improving quality-of-life for patients with hepatocellular carcinoma (HCC). Projects funded under the DRP are intended to rapidly advance a new idea or concept that has the potential to substantially impact our understanding of liver cancer to eliminate disparities and improve surveillance, early detection, and treatment of HCC in AI/AN persons and thereby reduce or eliminate HCC-related mortality. The infrastructure of the DRP will establish mechanisms to quickly respond to translational research opportunities within the Li-CAD P20 Program institutions that require support to advance hypotheses or confirm feasibility in order to justify larger resource investments. Developmental projects will include research in basic science, clinical science, and population-based studies, and will build collaborations between Li-CAD sites and other institutions with P20 Programs and SPOREs in liver cancer and disparities research. Developmental projects may encompass a wide range of liver cancer research and treatment areas, including basic science, etiology and prevention (primary and secondary), early detection, prognosis, therapeutics, and survivorship. Collectively, the DRP is structured to strengthen collaborations between Li-CAD sites and initiate interactions with other institutions with P20 Programs and SPOREs in liver cancer. DRP proposals will be supported based on their potential to mature an original idea or concept into a translational research project that will successfully attain independent funding, either within a subsequent P50 or from other government or foundation sources. In addition, the DRP is designed to attract senior investigators with diverse scientific expertise and junior investigators new to translational liver cancer research. The Specific Aims for the Developmental Research Program are to: 1. Stimulate the development of innovative, impactful, early-phase research studies that include multidisciplinary interactions with basic, clinical, and population scientists across the Li-CAD institutions; 2. Provide funding (1-2 years) and infrastructure (e.g., biospecimens, biostatistical support) to rapidly test the feasibility of original investigator-initiated projects in all areas of HCC research; 3. Prioritize funding to rapidly exploit new opportunities or support specific areas of strategic importance for advancing the translational research goals of the Li-CAD P20 Program; and 4. Monitor (and facilitate) the progress of each DRP project and consider their advancement to a full P50 SPORE project.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative Core
  • 批准号:
    10286758
  • 项目类别:
  • 资助金额:
    $22.21万
  • 财政年份:
    2021
  • 负责人:
    George Ioannou
  • 依托单位:
Developmental Research Program
  • 批准号:
    10706329
  • 项目类别:
  • 资助金额:
    $6.39万
  • 财政年份:
    2021
  • 负责人:
    George Ioannou
  • 依托单位:
Administrative Core
  • 批准号:
    10706311
  • 项目类别:
  • 资助金额:
    $19.08万
  • 财政年份:
    2021
  • 负责人:
    George Ioannou
  • 依托单位:
Risk stratification strategies and abbreviated MRI-based surveillance for early detection of HCC in high-risk AI/AN patients
  • 批准号:
    10706318
  • 项目类别:
  • 资助金额:
    $20.07万
  • 财政年份:
    2021
  • 负责人:
    George Ioannou
  • 依托单位:
海外基金